Ignite Creation Date:
2025-12-25 @ 2:18 AM
Ignite Modification Date:
2025-12-31 @ 11:55 PM
Study NCT ID:
NCT01454934
Status:
COMPLETED
Last Update Posted:
2023-06-22
First Post:
2011-10-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-12-09
Start Date Type:
ACTUAL
Primary Completion Date:
2014-05-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-05-02
Completion Date Type:
ACTUAL
First Submit Date:
2011-10-13
First Submit QC Date:
None
Study First Post Date:
2011-10-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-01-11
Results First Submit QC Date:
None
Results First Post Date:
2017-03-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-16
Last Update Post Date:
2023-06-22
Last Update Post Date Type:
ACTUAL